Home / Lu120819

Lu120819: mitochondrial modulation for diseases driven by cellular stress

Lu120819 is Luterion's lead investigational therapeutic platform. The candidate is being developed to modulate mitochondrial and immune-metabolic responses under pathological stress.

LUTERION's scientific strategy is based on the biological connection between mitochondrial dysfunction, maladaptive immune signaling, and impaired recovery after cellular or tissue injury.

Mitochondrial Dysfunction

Lu120819 is being developed for diseases where mitochondrial dysfunction contributes to pathological stress responses and impaired cellular recovery.

Immune Dysregulation

LUTERION's host-directed strategy focuses on immune-metabolic biology rather than direct pathogen- or symptom-only intervention.

Impaired Tissue Recovery

The platform is being explored in disease areas involving tissue injury, remodeling, and insufficient recovery from cellular stress.

See where Lu120819 is being developed.

View Pipeline